CoChat
Sign Up
Cited by 83Endometriosis Research and TreatmentEctopic Pregnancy Diagnosis and ManagementMenstrual Health and Disorders

Letrozole and desogestrel‐only contraceptive pill for the treatment of stage IV endometriosis

REMORGIDA, Valentino, ABBAMONTE, Luiza Helena, RAGNI, Nicola, FULCHERI, Ezio, FERRERO, Simone·2007·Australian and New Zealand Journal of Obstetrics and Gynaecology
DOI 10.1111/j.1479-828x.2007.00722.x
Open this paper in CoChat — free account

Abstract

Background: It has recently been suggested that aromatase inhibitors may effectively reduce pain symptoms related to the presence of endometriosis both in postmenopausal women and in subjects of reproductive age. Aims: This study aims to evaluate the effectiveness of a combination of letrozole and desogestrel in the treatment of pain symptoms related to the presence of endometriosis. Methods: This open‐label prospective study included 12 women with endometriosis‐related pain symptoms that were refractory to previous medical and surgical treatments. All women had previous laparoscopy documenting stage IV endometriosis. The treatment protocol included the daily oral administration of letrozole 2.5 mg (Femara®), desogestrel 75 µg (Cerazette®), elemental calcium 1000 mg and vitamin D 880 I.U. The scheduled treatment period was six months. Results: None of the women included in the study completed the six‐month treatment because all patients developed ovarian cysts; the median length of treatment was 84 days (range, 56–112). At interruption of treatment, all women reported significant improvements in dysmenorrhoea and dyspareunia. Pain symptoms quickly recurred at three‐month follow up. There were no severe adverse effects of treatment; no significant change in the mineral bone density was observed during treatment. Conclusions: The combination of letrozole and desogestrel induces a relief of pain symptoms in women with endometriosis but it causes the development of ovarian cysts. Pain symptoms quickly recur after the completion of treatment.

Integrity signals

Registry

Crossref · 10.1111/j.1479-828x.2007.00722.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In an open-label prospective study of 12 women with stage IV endometriosis, DSG-POP plus letrozole treatment was associated with significant improvement of dyspareunia and chronic pelvic pain, but none completed 6-month protocol due to functional ovarian cysts.

    “Unfortunately, none of the patients completed the 6months treatment protocol, due to the development of functional ovarian cysts, with a median length of treatment of 84 days (range 56-112).”

    From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [43]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
REMORGIDA, V., ABBAMONTE, L. H., RAGNI, N., FULCHERI, E., & FERRERO, S.
Affiliations
Ospedale Policlinico San Martino (IT)
Corresponding author
FERRERO, Simone
ORCID
Venue
Australian and New Zealand Journal of Obstetrics and Gynaecology
Publisher
Wiley
Published
2007-06
Volume
47
Issue
3
Pages
222-225
ISSN
  • 0004-8666 (ISSN-L)
  • 1479-828X
DOI
10.1111/j.1479-828x.2007.00722.x
OpenAlex
W2164864911
Cited by
83
References
13
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 7 · 2013: 3 · 2012: 5
FWCI
8.46
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 4 d)
Locations
  • Australian and New Zealand Journal of Obstetrics and Gynaecology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
Keywords
endometriosis, letrozole, desogestrel, aromatase inhibitors, endometriosis-associated pain, dysmenorrhea, dyspareunia, ovarian cysts, treatment discontinuation, pain recurrence, stage IV endometriosis, bone mineral density
MeSH terms
Letrozole, Adult, Contraceptives, Oral, Synthetic, Drug Therapy, Combination, Endometriosis, Female, Humans, Nitriles, Ovarian Cysts, Prospective Studies, Triazoles, Desogestrel, Pelvic Pain, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review